Market Newsdesk

Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel

Expansions Expected to Support Process Development and Production of Current and Future Cell Transplant Programs

CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the opening of a new research and development (R&D) facility in Carlsbad, California, and the expansion of its Good Manufacturing Practice (GMP) manufacturing facility based in Jerusalem, Israel. Lineage’s new Carlsbad facility will broaden the Company’s R&D capabilities in the U.S. and support the development of current and future allogeneic cell transplant programs. The expansion of Lineage’s Israel-based facility will increase the Company’s infrastructure, including development and optimization of larger-scale clinical manufacturing processes, and continued execution under its ongoing collaboration with Roche and Genentech for RG6501 (OpRegen^®), a retinal pigment epithelium cell replacement therapy which has completed enrollment in a Phase 1/2a clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

“We have elected to increase our R&D footprint at our existing GMP manufacturing facility and establish a new R&D facility in Carlsbad, California,” stated Brian M. Culley, Lineage CEO. “These steps will permit us to expand our process development and analytical testing capabilities and conduct exploratory work on future programs, whether owned by us or our current or future partners. This move also is expected to reduce our reliance on certain vendors, which may reduce costs and risks of timeline uncertainty or supply chain disruption. The additional capacity also can help us become an even more capable partner in prospective alliances for new products and allow us to explore additional uses for our current cell transplant programs.”

Mr. Culley added, “Challenges in the biotech sector are unlikely to persist indefinitely. We believe it is important to take steps, even in this environment, to be positioned for a future recovery. The modest investments we are making today, partially offset by the termination of the lease for our research facility in Alameda, California in January of next year, will help centralize our operations and put us in a position of greater readiness for future success.”

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential benefits of the new and expanded facilities to the Company and its operations, including the broadening of the Company’s R&D capabilities, increasing development and optimization of larger-scale clinical manufacturing processes, the expansion of the Company’s process development and analytical testing capabilities and ability to conduct exploratory work on future programs, the increase in the Company’s manufacturing facilities, the decreased reliance on certain vendors, the reduction in costs and risks of timeline uncertainty and supply chain disruption, and the improvement in the Company’s position of greater readiness for future success. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that potential benefits of the new and expanded facilities to the Company and its operations may not be realized as quickly as expected or at all; that we may need to allocate our cash to unexpected events and expenses causing us to use our cash more quickly than expected; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that we may not establish new partnerships or expand existing collaborations; that we do not successfully broaden awareness of our mission or accomplishments; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005286/en/

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

([email protected])

(442) 287-8963

LifeSci Advisors

Daniel Ferry

([email protected])

(617) 430-7576

Russo Partners – Media Relations

Nic Johnson or David Schull

([email protected])

([email protected])

(212) 845-4242

KEYWORDS: California United States North America Israel Middle East

INDUSTRY KEYWORDS: Oncology Health Other Health Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Logo

Agilent Announces Enhanced 8700 LDIR Chemical Imaging System for Microplastics Analysis

Increased testing capacity will provide greater understanding of microplastics contamination in the environment

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced the release of its enhanced 8700 LDIR Chemical Imaging System, which has been further optimized for the analysis of microplastics in environmental samples. This newly improved package includes Clarity 1.5 software – a significant upgrade that advances the speed of analysis, enhances spectral acquisition, transformation, and library matching, and provides automated workflows for direct analysis of microplastics on a filter substrate. An innovative, redesigned sample holder allows the on-filter sample to be presented to the instrument more easily and consistently.

The prevalence of microplastics in the environment is a growing concern worldwide, prompting greater scrutiny from governments and increased monitoring of rivers and oceans by environmental agencies. Adequately assessing the prevalence of microplastics in the environment requires researchers to determine the size, shape, and chemical identity of plastic particles in a sample. As smaller particles are thought to be the most biologically relevant, this analysis must extend to particles on the micron scale.

Slow and complex analysis solutions are a major challenge to microplastics analysis and have hindered studies of real-world systems. Additionally, method variability limits the comparability of studies, making trends difficult to assess. Vibrational spectroscopy methods such as FTIR and Raman microscopy provide a useful alternative, but each faces limitations due to the excessive time of analysis and method complexity.

The Agilent 8700 LDIR brings high-speed analysis and ease of use to infrared spectroscopy and has rapidly emerged as the benchmark technique for the analysis of microplastics particles. The development of on-filter analysis for this platform marks another leap forward in speed and throughput. The ability to significantly increase testing volumes will allow a greater understanding of the extent of microplastics contamination in the environment and will help facilitate the development of appropriate standards and regulations.

Geoff Winkett, vice president and general manager for Agilent’s Molecular Spectroscopy Division, discussed the announcement’s impact. “When I speak with microplastics researchers, a recurring question is how to make testing faster and easier, as there is a real concern that the limited sample numbers that can be realistically processed may be masking the true nature of the issue,” he said. “The fact is that other currently available techniques are too slow and cannot capture the extent of the microplastics load in drinking and environmental waters. Fast and easy-to-use analysis methods such as the 8700 LDIR provide an essential and much-needed alternative that enables researchers to increase sampling over area or time to address these limitations.”

As a leading provider of analytical solutions for food and environmental analysis, Agilent is committed to delivering technology that improves user outcomes for academic research settings and commercial testing facilities. The release of the enhanced 8700 LDIR is expected to strengthen its leadership position in this growing market.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005313/en/

Naomi Goumillout

Agilent Technologies

+1.781.266.2819

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Electronic Design Automation Chemicals/Plastics Technology Manufacturing Software Hardware

MEDIA:

Logo

Wolfspeed, Inc. Announces Date of Fiscal First Quarter Earnings Call and Investor Day for October 2022

DURHAM, N.C.–(BUSINESS WIRE)–
Wolfspeed, Inc. (NYSE: WOLF), the global leader in Silicon Carbide technology, will conduct a conference call and audio webcast to discuss its first quarter fiscal 2023 results on Wednesday, October 26^th, 2022, at 5:00 pm Eastern Time.

The Company will also host an Investor Day event at the New York Stock Exchange on Monday, October 31^st, at 8:00 am Eastern Time. Wolfspeed’s executive leadership team will provide an update on the business and the Company’s long-term outlook.

A live webcast of the earnings conference call and Investor Day, along with the earnings release and Investor Day materials will be available on Wolfspeed’s Investor Relations website at investor.wolfspeed.com.

About Wolfspeed, Inc.

Wolfspeed (NYSE: WOLF) leads the market in the worldwide adoption of Silicon Carbide and gallium nitride (GaN) technologies. We provide industry-leading solutions for efficient energy consumption and a sustainable future. Wolfspeed’s product families include Silicon Carbide materials, power devices and RF devices targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. We unleash the power of possibilities through hard work, collaboration and a passion for innovation. Learn more at www.wolfspeed.com.

Wolfspeed^® is a registered trademark of Wolfspeed, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005224/en/

Media Relations:

Melinda Walker

Director, Corporate Communications

818-261-4585

[email protected]

Investor Relations:

Tyler Gronbach

VP, Investor Relations

919-407-4820

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Technology Mobile/Wireless Semiconductor 5G Other Technology Telecommunications Alternative Energy Energy Hardware

MEDIA:

Logo

Mirion Technologies Appoints Michael Rossi as President of Mirion Medical

ATLANTA–(BUSINESS WIRE)–
Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment.

Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing levels of responsibility. Michael also brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International to the Mirion team. Michael earned a Bachelor of Science in Pharmacy degree from the University of the Sciences – Philadelphia College of Pharmacy and carries the Authorized Nuclear Pharmacist Certification from Butler University. Michael has also served on several Boards of Directors and remains a Licensed Pharmacist in the state of Pennsylvania.

“I am thrilled to welcome Michael to the Mirion team,” said Tom Logan, Mirion’s CEO. “Michael has a unique blend of domain experience and leadership qualities in the nuclear medicine space. His appointment comes at an exciting time for the Company, as we aim to drive organic and inorganic growth and margin expansion across our medical business. I am confident that Michael will accelerate the attainment of our healthcare ambitions.”

“I am incredibly excited to be joining Mirion Medical at such an impactful time in the Company’s growth trajectory,” added Michael Rossi. “What Tom and the team have built over the last few years is truly impressive and I look forward to building off the solid momentum with my new colleagues.”

About Mirion

Mirion Technologies is a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Headquartered in Atlanta (GA – USA), Mirion employs around 2,800 people and operates in 13 countries. For more information, and for the latest news and content from Mirion, visit ir.mirion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005192/en/

For investor inquiries:

Jerry Estes

[email protected]

For media inquiries:

Matthew Maddox

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Science Radiology Data Analytics Research Health Energy Professional Services Nuclear

MEDIA:

Posted on October 3, 2022 8:03 am

Nexstar Media Closes Acquisition of The CW Network

Nexstar Media Closes Acquisition of The CW Network

Television Industry Leader and Technology and Media Investor, Dennis Miller, Named President

Mark Pedowitz to Exit as Chairman/CEO After 11-Year Tenure

IRVING, Texas & LOS ANGELES–(BUSINESS WIRE)–
Nexstar Media Group, Inc. (NASDAQ: NXST, “Nexstar”) announced today that it has closed its previously announced acquisition of a 75% ownership interest in The CW Network, LLC (“The CW” or the “Company”) from co-owners Warner Bros. Discovery (Nasdaq: WBD) and Paramount Global (Nasdaq: PARA, PARAA), who will each retain a 12.5% ownership interest in The CW. Nexstar also announced that Dennis Miller has been named President of The CW, effective immediately. Mr. Miller has served as a member of Nexstar’s Board of Directors since 2014 and has stepped down from the Board in connection with his appointment. Nexstar has initiated a search for a new member of its Board of Directors.

Mr. Miller is assuming leadership of The CW from Mark Pedowitz, who, after serving as Chairman and CEO of The CW for the past 11 years, has announced his intention to revive his successful production company. Mr. Pedowitz will provide support to The CW, Nexstar, and Mr. Miller in a streamlined transition. Throughout his tenure, Mr. Pedowitz was instrumental in charting the expansion of The CW and bringing some of the most groundbreaking and generation-defining programming in television to millions of viewers.

“Dennis Miller brings a unique skill set of proven television, media, and technology industry expertise, as well as venture capital experience to the role of President at The CW. His understanding and ability to unlock value from media assets by delivering high-quality, profitable entertainment, will serve the network, its viewers, its partners and CW affiliates around the country extremely well. We are confident his background, experience and relationships will allow Nexstar to deliver on the value of this transaction for our shareholders,” said Perry Sook, Nexstar’s Chairman and Chief Executive Officer. “I look forward to working with Dennis and Sean Compton, Nexstar’s President of Networks, to build on the foundation that Mark Pedowitz and his team have established at both the CW Network and the CW App. We sincerely thank Mark for his many years of service to The CW and wish him the very best in his future endeavors.”

Mr. Miller is a seasoned television executive with a successful long-term record of success and value creation in the industry. He has held senior executive positions at Sony Pictures Entertainment, Lionsgate Television and Turner Network Television. He most recently served as Chairman of Industrial Media until its sale to Sony Pictures Television earlier this year. Industrial Media is an independent production group whose companies collectively produce more than 94 television shows airing across 34 networks, including some of the most popular shows on television including “American Idol” on ABC; the “Matchmaker” series on Netflix; the Selena Gomez cooking show and the upcoming “The Climb” with Jason Momoa both on HBO; the upcoming Elton John documentary on Apple+; and, the dominant franchise for the last five years on Discovery, “90 Day Fiancé.” Mr. Miller also has significant experience as a TMT investor, having spent several years as a General Partner at Spark Capital and a Managing Director at Bear Stearns’ venture arm, Constellation Ventures. He began his career in the entertainment and tax department of the law firm of Manatt, Phelps, Rothenberg and Tunney.

Commenting on his appointment, Mr. Miller said, “It has been a privilege to serve on Nexstar’s Board of Directors for the last eight years and work closely with Perry and the other distinguished members of the Board during a period of transformational growth and success for the Company. This appointment perfectly aligns my intimate knowledge of Nexstar’s business approach and operating goals to realize the value inherent in The CW. I look forward to working with Perry, Sean and the team to leverage the experience and business relationships built over my career in the media, and technology industries to create new value for viewers, advertisers, affiliates, and Nexstar shareholders.”

“It’s been an honor to serve as the Chairman and CEO of The CW Network for the last 11 years and I am very proud of what our exceptional teams have accomplished together over that time,” said Mr. Pedowitz. “It was the right moment for me to hand over the leadership baton and I am excited to move on to the next chapter of my professional career where I can pursue a different set of interests. I am confident Perry, Sean, Dennis and the Nexstar team’s ability to usher in the next phase of growth and success for the CW Network and look forward to supporting them during the transition period.”

About Nexstar Media Group, Inc.

Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that produces and distributes engaging local and national news, sports and entertainment content across television, streaming and digital platforms, including more than 290,000 hours of original video content each year. Nexstar owns America’s largest local broadcasting group comprised of top network affiliates, with 200 owned or partner stations in 116 U.S. markets reaching 212 million people. Nexstar’s national television properties include The CW, America’s fifth major broadcast network, NewsNation, America’s fastest-growing national news and entertainment cable network reaching 70 million television homes, popular entertainment multicast networks Antenna TV and Rewind TV, and a 31.3% ownership stake in TV Food Network. The Company’s portfolio of digital assets, including The Hill and BestReviews, are collectively a Top 10 U.S. digital news and information property. In addition to delivering exceptional content and service to our communities, Nexstar provides premium multiplatform and video-on-demand advertising opportunities at scale for businesses and brands seeking to leverage the strong consumer engagement of our compelling content offering. For more information, please visit Nexstar.tv.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005198/en/

Investors:

Joseph Jaffoni or Jennifer Neuman

JCIR

212/835-8500

Media:

Gary Weitman

EVP/Chief Communications Officer

Nexstar Media Group, Inc.

972/373-8800 (office)

[email protected]

KEYWORDS: United States North America California Texas

INDUSTRY KEYWORDS: TV and Radio Entertainment

MEDIA:

Logo

They’re Baaack … Spooky Sips Return to Applebee’s – Just in time for Halloween

Enjoy Applebee’s Scary-Delicious Cocktails for just $6!

GLENDALE, Calif.–(BUSINESS WIRE)–
BOO-zy cocktails are back at Applebee’s in celebration of the spookiest time of the year! Fall fanatics and guests alike, can celebrate all month long with the return of Applebee’s latest frighteningly delicious $6 Mucho Cocktails™, Spooky Sips.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005186/en/

Cure your cravings with the Tipsy Zombie, made with Bacardi Superior and Applebee’s proprietary blend of passion fruit, pineapple, cherry and lime topped with a gummy brain and melon liqueur. Or, sink your teeth into Dracula’s Juice, a mouth-watering frozen berry creation featuring both Patron Silver and Bacardi Superior. Trick-or-treat yourself to these cocktails for only $6 each!

Applebee’s Mucho Cocktails are made with premium spirits and served in a signature Mucho glass. Plus, guests can enjoy these $6 Spooky Sips To Go at participating locations.*

“Getting in on the Halloween fun is just another reason for our guests to visit their neighborhood Applebee’s bar,” said Patrick Kirk, vice president of beverage innovation at Applebee’s. “With the return of our frighteningly delicious Spooky Sips, they can treat themselves with a wicked-good deal at Applebee’s. Hurry on in for a howlin’ good time!”

To order Applebee’s To Go or Delivery, visit Applebees.com or the Applebee’s mobile app (iOS, Google). For even more exclusive deals and specials, guests can sign up to be a part of the neighborhood. Join Club Applebee’s and receive a welcome offer!

*Must be 21+. Void where prohibited. Tax & gratuity excluded. Available for dine-in only except where carry-out alcohol is permitted by law. Participation may vary. While supplies last.

About Applebee’s®

As one of the world’s largest casual dining brands, Applebee’s Neighborhood Grill + Bar serves as America’s kitchen table, offering guests a lively dining experience that combines simple, craveable American fare with classic drinks and local drafts. Applebee’s makes it easy for family and friends to connect with one another, whether it’s in a dining room or in the comfort of a living room, Eatin’ Good in the Neighborhood™ is a familiar and affordable escape from the everyday. Applebee’s restaurants are owned and operated by entrepreneurs dedicated to more than serving great food, but also building up the communities that we call home. From raising money for local charities to hosting community fundraisers, Applebee’s is always Doin’ Good in the Neighborhood®. Applebee’s franchise and company-operated operations consisted of 1,673 Applebee’s restaurants in the United States, two U.S. territories and 11 countries outside the United States as of August 9, 2022. This number does not include two domestic Applebee’s ghost kitchens (small kitchens with no store-front presence, used to fill off-premise orders) and eight Applebee’s international ghost kitchens. Applebee’s is franchised by subsidiaries of Dine Brands Global Inc. [NYSE: DIN], which is one of the world’s largest full-service restaurant companies.

Follow us:

Instagram: @applebees

Twitter: @applebees

Facebook: www.facebook.com/applebees

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005186/en/

For media inquiries, email us at [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage Wine & Spirits

MEDIA:

Logo

Photo

They’re Baaack … Spooky Sips Return to Applebee’s – Just in time for Halloween (Photo: Business Wire)

HilltopSecurities Launches 2^nd Annual Hilltop Hunt

Starting Oct. 5, Online Contest Offers Texas K-8 Teachers Chance to Win Share of $50,000 in Donations and Prizes

DALLAS–(BUSINESS WIRE)–
On Oct. 5, 2022, World Teachers’ Day, Hilltop Securities Inc. (HilltopSecurities) will launch its second annual virtual Hilltop Hunt, providing Texas K-8 public and charter school educators with the chance to win a share of $50,000 in prizes.

“HilltopSecurities has a deep commitment to supporting public education, and the Hilltop Hunt is a fun way we can give back to Texas schools and honor the teachers who have such a positive impact on our future generations,” said HilltopSecurities President and CEO Brad Winges. “When we started the Hilltop Hunt last year, we were excited to see how many Texas teachers and students embraced the contest and what it meant to their districts.”

Theme of this year’s hunt: “Where’s Mo?”

Hilltop’s mascot, Mo the Buffalo, loves to roam and participants in this year’s contest will follow his tracks to see where he goes next as he visits his favorite Texas landmarks. The contest takes place entirely online at HilltopHunt.com, and for 10 business days, beginning on Oct. 5, participants will see daily riddles that provide clues about Mo’s travels. By answering the riddles correctly, contestants will be entered into a drawing to win a share of the prizes. The fewer guesses it takes to answer the riddle correctly, the more entries they’ll earn. The contest will remain open until Oct. 22 with past riddles available to anyone who joins, even after the contest already has begun.

There is no purchase necessary to enter or win, and the contest is open to anyone employed in a teaching role by a public school district or charter school in Texas teaching kindergarten through eighth grade.

Over $50,000 in prizes

Once the contest has concluded, a drawing will be held to choose five Gold Prize and 10 Silver Prize winners. Each Gold Prize winner will receive a $10,000 donation to the ISD Foundation, or comparable eligible teacher support organization, of their choice, plus a pizza party for their homeroom class. The Silver Prize winners will win a pizza party for their homeroom class.

Once again, HilltopSecurities representatives plan to travel to the schools of each Gold Prize winner to present their prize and thank them for taking part and doing so much to make a difference in the lives of their students. Last year’s check presentations took place in Denton, Kerrville, Highland Park, Corpus Christi, Lubbock, Boerne, Celeste, and Pflugerville.

About Hilltop Securities Inc.

Hilltop Securities Inc. delivers forthright advice and tailored solutions to municipal issuers, institutions, broker-dealers, and individuals. The full-service investment bank and registered investment adviser is headquartered in Dallas, Texas, with offices across the United States. Areas of focus include public finance; municipal and taxable fixed income underwriting, sales, and trading; retail brokerage services; securities clearing; structured finance; and securities lending. A wholly owned subsidiary of Hilltop Holdings Inc. (NYSE: HTH), HilltopSecurities’ affiliates include Momentum Independent Network Inc., PlainsCapital Bank, and PrimeLending. Learn more at www.HilltopSecurities.com. Member: NYSE/FINRA/SIPC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005074/en/

Hilltop Holdings Inc.

Ben Brooks

214.252.4047

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Finance Banking Professional Services Philanthropy Other Philanthropy Foundation Primary/Secondary Asset Management Education

MEDIA:

Posted on October 3, 2022 8:03 am

Hologic Rings Nasdaq Opening Bell to Kick Off Breast Cancer Awareness Month

Hologic Rings Nasdaq Opening Bell to Kick Off Breast Cancer Awareness Month

Tennis Legend Martina Navratilova Joins Hologic to Highlight Importance of Regular Screenings

MARLBOROUGH, Mass.–(BUSINESS WIRE)–
Hologic, Inc. Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell today to mark the beginning of Breast Cancer Awareness Month. This is the 16^th time that Hologic (Nasdaq: HOLX), an innovative medical technology company and the pioneer of 3D mammography, will ring the bell to raise awareness about breast cancer.

MacMillan will be joined by Hologic employees and members of the Women’s Tennis Association (WTA), including tennis legend and breast cancer survivor Martina Navratilova and WTA President Micky Lawler, as part of a multi-year partnership between Hologic and the WTA to champion women’s health and equality.

“We are honored to stand alongside the women of the WTA in recognizing Breast Cancer Awareness Month as we continue to underscore the importance of preventive care and annual mammography screening,” said MacMillan. “Our recently released findings from the second year of the Hologic Global Women’s Health Index highlight the unfortunate reality that more than 2 billion women worldwide weren’t tested for any type of cancer, including breast cancer, in the past 12 months, making the work we do to increase awareness even more important.”

The Hologic Global Women’s Health Index, one of the world’s largest studies on women’s well-being, examines critical markers for health by country and territory, and over time. It identifies barriers to preventive care for women and provides a framework for governments, business leaders, nonprofit organizations, scholars and others to achieve progress.

“As a woman who was diagnosed with breast cancer after a routine mammogram, I know firsthand how important breast cancer screening is,” said Navratilova. “While progress has been made, Hologic’s research shows that far too many women are not getting the screenings they deserve. I’m proud to stand with Hologic this Breast Cancer Awareness Month and share my story in hopes of encouraging other women to schedule their mammograms and prioritize their health.”

The bell ringing is one of many activities that Hologic and the WTA have used to spread the message of prevention, early detection and early treatment since the groundbreaking partnership began in March of this year. Throughout Breast Cancer Awareness Month, the two organizations will continue to bring much-needed attention to the critical issue of women’s health during tournaments, at special events and through public campaigns.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to [email protected].

Source: Hologic, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005073/en/

Media Contact:

Jane Mazur

Vice President, Corporate Communications

508.263.8764

[email protected]

Investor Contact:

Ryan Simon

Vice President, Investor Relations

858.410.8514

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Research Entertainment Sports General Health Oncology Consumer Medical Devices Celebrity Tennis Science Women Health

MEDIA:

Logo

Zones Partners with Thoughtworks to Speed e-Ordering Process while Continuing its Digital Transformation Journey

CHICAGO–(BUSINESS WIRE)–Thoughtworks (NASDAQ: TWKS), a global technology consultancy that integrates strategy, design, and engineering, today announced its collaboration with Zones, LLC, a global IT solution provider, to augment and accelerate the e-ordering process for Zones’ customers in more than 100 countries around the world. As part of its digital transformation journey, Zones is also consolidating and modernizing its enterprise eCommerce platform to enable it to better adapt and globally scale to meet new levels of business agility.

This initiative includes streamlining the customer ordering process through multiple electronic channels to significantly reduce turnaround time and support multiple geographic locations and currencies. With a more domain-driven approach to strategy, design, and delivery, Zones’ IT organization will also be better empowered to support new routes to market, new channels, and new services as the business expands and grows.

“In today’s digital era, where customers have come to expect high levels of speed and reliability, it’s more important than ever to always be driving change and developing innovative new services that delight customers,” said Saad Ayub, Chief Digital and Innovation Officer, Zones, LLC. “As part of our digital transformation, we are continually listening to our customers, and with Thoughtworks, we’re simplifying order processing, reducing operational complexity, and improving customer response times.”

The Zones and Thoughtworks engineering teams will work side-by-side within a service-oriented architecture, microservices, and DevOps culture. Together, the teams will re-design Zones’ global order processing platform through a customer-driven lens, taking advantage of agile capabilities and engineering practices such as lean product development, iterative planning and delivery, and continuous integration and delivery.

“It’s more critical now than ever for global companies such as Zones to seize the opportunities that modern technology provides for increased business agility and accelerated innovation and evolution on a global scale,” said Chris Murphy, Chief Executive Officer, Thoughtworks North America. “Since our inception 29+ years ago, Thoughtworks has been pioneering the trends and approaches that enable enterprise modernization, including flexible microservices and evolutionary architectures. We look forward to partnering with Zones to accelerate and enable its customer experience-driven digital transformation.”

Supporting resources:

• Keep up with Thoughtworks news by visiting the company’s website
• Follow Thoughtworks on Twitter, LinkedIn and YouTube.

– ### – <TWKS915>

About Zones

Zones, LLC is a global IT solution provider that delivers products and services to help companies make a complete digital transformation – from desktop to the data center – to the cloud and beyond. Zones’ expertise is reflected in their business model focusing on Digital Workplace, Cloud & Datacenter, NextGen Networking, Cybersecurity, and Managed/Professional/Staffing services. They leverage a deep portfolio from top-tier technology brands to enable scalability, security, and efficient IT deployments. They utilize the highest technical certification levels from key partners, including Microsoft, Cisco, Dell Technologies, HP Inc., HPE, Apple, Adobe, Intel, Lenovo, and others. Zones operates in more than 100 countries, with multiple regional and executive offices, several distribution facilities, IT partners, and several service affiliates worldwide. As a certified Minority Business Enterprise (MBE) and holder of an elite Corporate Plus Certification, they’ve proven their ability to support many of the world’s largest corporations. For additional information, visit the company’s website at www.zones.com.

Follow Zones, LLC on Twitter @Zones, and LinkedIn and Facebook.

About Thoughtworks

Thoughtworks is a global technology consultancy that integrates strategy, design and engineering to drive digital innovation. We are 12,000+ people strong across 50 offices in 17 countries. Over the last 25+ years, we’ve delivered extraordinary impact together with our clients by helping them solve complex business problems with technology as the differentiator.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005049/en/

Media:

Linda Horiuchi, global head of public relations

Email: [email protected]

Phone: +1 (646) 581-2568

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Security Technology Software Electronic Commerce Networks Internet

MEDIA:

Logo